Where does Glenmark Pharmaceuticals make most of its revenue?

India: 34% of revenue by region in fiscal year 2025, followed by North America (23%).

What companies are similar to Glenmark Pharmaceuticals?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Mankind Pharma Limited (MANKIND.NS), Aurobindo Pharma Limited (AUROPHARMA.NS), Lupin Limited (LUPIN.NS), Alkem Laboratories Limited (ALKEM.NS).

Glenmark Pharmaceuticals Limited (GLENMARK.NS) Stock

About Glenmark Pharmaceuticals Limited

Glenmark Pharmaceuticals Limited, together with its subsidiaries, research, develops, manufactures, and sells generics, specialty medicines, and over the counter (OTC) pharmaceutical products in India, North America, Europe, and internationally. The company provides various products in the therapeutic areas of dermatology, respiratory, oncology, cardiology, diabetes, gynecology, gastroenterology, ...

At a glance

In Q2 2026 (the quarter ended September 30, 2025) revenue was 60.04 billion INR, up 76.6% from a year before. India was its largest region in fiscal year 2025, with 34% of revenue.

Figures from company filings; latest fiscal year ended March 31, 2025.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.